Ergomed plc Ergomed Annual General Meeting Statement (3986O)
10 Junio 2022 - 1:01AM
UK Regulatory
TIDMERGO
RNS Number : 3986O
Ergomed plc
10 June 2022
PRESS RELEASE
Annual General Meeting Statement
Guildford, UK - 10 June 2022: Ergomed plc (LSE: ERGO) ('Ergomed'
or the 'Company'), a company focused on providing specialised
services to the pharmaceutical industry, announces the following
update from Dr Miroslav Reljanović, Executive Chairman, in advance
of the Company's Annual General Meeting ('AGM') to be held this
morning at 9.30am BST .
"Ergomed started 2022 from a position of strength, with a robust
order book and strong sales momentum continuing from prior years.
Over the first few months of this year, the Company has built
further on this momentum, thanks to our resilient services-based
business model and the global strength of our offering following
the successful integration of businesses acquired in prior years.
Underpinning this, Ergomed is in a robust financial position with a
strong balance sheet and cash generation.
"The Company has made further significant strategic progress in
the current year. Our organic growth has continued with
year-to-date revenues increasing in line with prior trends. Our
expansion into new territories is ongoing, with a new legal entity
established in France and others in progress in Romania, Italy,
Ireland and Portugal. We have also continued to further strengthen
the Company's leadership team, attracting senior executives with
significant prior experience in the CRO, PV and pharma services
sectors, and announced today the appointment of Anne Whitaker as a
new independent Non-Executive Director.
"Alongside this organic growth, Ergomed continues to execute its
disciplined M&A strategy, focused on value-enhancing and
strategic acquisitions which strengthen our position on a global
scale. In February this year we announced the acquisition of ADAMAS
Consulting Group Limited, an international specialist consultancy
offering a full range of independent quality assurance services.
The transaction was immediately earnings accretive, and further
growth synergies and strategic benefits are expected in future
years.
" With continuing strong sales and order book growth, together
with effective cost management, in 2022 Ergomed continues to
demonstrate its resilience and defensive characteristics,
notwithstanding the challenging macro-economic environment, and the
Board expects to deliver the anticipated trading growth and
financial results for the full year in line with current market
expectations.
"In accordance with our usual practice, we will provide more
detail on current trading and the outlook for the 2022 financial
year in the Company's July Trading Update.
"On behalf of the Board, I would like to thank all the Company's
staff and shareholders for their continuing support, and we look
forward to the rest of this year with confidence and
enthusiasm."
ENDS
Enquiries:
Ergomed plc Tel: +44 (0) 1483 402 975
Miroslav Reljanović (Executive
Chairman)
Richard Barfield (Chief Financial Officer)
Keith Byrne (Senior Vice President,
Capital Markets & Strategy)
Numis Tel: +44 (0) 20 7260 1000
Freddie Barnfield / Euan Brown (Nominated
Adviser)
James Black (Broker)
Peel Hunt (Joint Broker) Tel: +44 (0) 20 7418 8852
James Steel / Dr. Christopher Golden
Consilium Strategic Communications Tel: +44 (0) 20 3709 5700
Chris Gardner / Matthew Neal / Angela ergomed@consilium-comms.com
Gray
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical
industry spanning all phases of clinical development, post-approval
pharmacovigilance and medical information. Ergomed's fast-growing
services business includes an industry-leading suite of specialist
pharmacovigilance (PV) solutions, integrated under the
PrimeVigilance brand, a full range of high-quality clinical
research and trial management services under the Ergomed brand
(CRO) and mission-critical regulatory compliance and consulting
services under the ADAMAS brand. For further information, visit:
http://ergomedplc.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
AGMUKAKRUBUNRAR
(END) Dow Jones Newswires
June 10, 2022 02:01 ET (06:01 GMT)
Ergomed (LSE:ERGO)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Ergomed (LSE:ERGO)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024